LSD Treatment for Persons With Alcohol Use Disorder

Official title

Investigating the Efficacy and Microstructural Plasticity of LSD Treatment in Patients With Alcohol Use Disorder: A Multicenter, Double-blind, Randomized, Active-placebo-controlled Phase II Neuroimaging Study.

Overview

Alcohol use causes more overall harm than any other drug and is the seventh leading risk factor for both deaths and disability-adjusted life years. Alcohol use disorders (AUD) are among the most common and undertreated mental disorders in developed countries. Pharmacological and psychotherapeutic treatments only show limited efficacy, and around 60% of the patients relapse in the short term after withdrawal. Lysergic acid diethylamide (LSD) was investigated in numerous clinical trials during the 1950s and 1960s. Specifically, the use of LSD in the treatment of AUD was investigated extensively. A pooled analysis of six historical clinical trials demonstrated that a single dose of LSD significantly reduced alcohol use at three and six months after LSD administration. However, these trials are limited by several factors, including the use of diagnostic standards that are no longer up to date, single, high-dose treatment regimes, missing biological assessment for alcohol use, and no consequent assessment of blinding. This trial will assess the efficacy and safety of two moderate to high doses of LSD to decrease alcohol consumption in patients with AUD. The trial has a double-blind, active placebo-controlled, randomized, parallel design and will be conducted in specialized treatment centers for addictive disorders in Switzerland. The study will include 128 patients who have undergone detoxification. Participants will be allocated to one of the two intervention arms (1:1 allocation). Each arm comprises nine study visits (no drug administration) and two study days (involving LSD administration) within 30 weeks. Patients allocated to the control intervention (active placebo group) will receive 10 µg LSD on the first study day and either 10 or 20 µg LSD on the second study day. Patients allocated to the treatment intervention will receive 150 µg LSD on the first study day and either 150 µg or 250 µg LSD on the second study day. The dose will be retained or increased depending on the patient's individual response on the first study day. Participants in the control intervention will be offered to attend an open-label LSD session (150 µg) at week 31. The open-label phase will comprise three additional visits. This trial will further compare the effectiveness of LSD-assisted therapy in both group and individual therapeutic settings. To this end, participants in both drug conditions will be randomly assigned to group or individual settings. The primary outcome is the mean of percent heavy drinking days after administration of two doses of LSD during the 12 weeks following the second administration. Secondary objectives: The second aim of this study is to explore long-term changes in the cortical thickness, white matter microstructure, resting state functional connectivity (rs-FC) and cerebral blood flow (CBF) of regions associated with addiction pathophysiology. Furthermore, we will assess alterations in depressive symptoms, anxiety, and persisting effects of LSD. We will also assess biological markers of alcohol use and several predictors for treatment-response (genetics, personality traits, blinding, expectancy, and quality of acute drug effects). Lastly, we will compare LSD treatment within a group setting with treatment within an individual setting.

Detailed description

Patients will be followed up six months after the second administration in the double-blind phase. At this time point, a predefined subset of the questionnaires used in the main study will be administered (TLFB, SIP-2R, OCDS, drinking goals, self-efficacy, BSCL, BDI, and BAI; see below).

During the open-label phase, patients will be assessed one month after administration. This assessment will include a subset of questionnaires (TLFB, OCDS, BSCL, BAI, BDI, CHIME, WHOQOL-BREF, drinking goals, self-efficacy, and WVQ; see below). In addition, the open-label phase will include assessments of acute drug effects, expectancy, and adverse events (see below).

Interventions

• Drug LSD
  Moderate to high dose LSD
• Drug Active placebo
  Low dose LSD

Primary outcome measures

• Percent heavy drinking days [Time frame: Period of three months after the second administration]

Secondary outcome measures (12)

• Cortical thickness measured with MRI [Time frame: One month after the first administration, one month after second administration]
• The volume of the striatum measured with MRI [Time frame: One month after the first administration, one month after second administration]
• White matter microstructure measured with MRI [Time frame: One month after the first administration, one month after second administration]
• Days to first heavy drinking day [Time frame: One month after the first administration, one, two, and three months after the second administration]
• Days to first drinking day [Time frame: One month after the first administration, one, two, and three months after the second administration]
• Percent days abstinent [Time frame: One month after the first administration, one, two, and three months after the second administration]
• Drinks per drinking day [Time frame: One month after the first administration, one, two, and three months after the second administration]
• Percent heavy drinking days [Time frame: One month after the first administration]
• Adverse consequences of alcohol use [Time frame: Three months after the second administration]
• Craving [Time frame: Three weeks after the first administration, three weeks, two and three months after the second administration]
• Ethyl glucuronide [Time frame: Three months after the second administration]
• Phosphatidylethanol [Time frame: At each administration and three months after the second administration]

Eligibility criteria

Inclusion criteria

• Age ≥ 25 years
• Participants must meet the DSM-5 criteria for a moderate to severe alcohol use disorder and must intend to stop or decrease their drinking for at least the duration of the study
• Participants must have underwent an alcohol detoxification within the 60 days prior to screening or, in cases where no detoxification is necessary, must have been abstinent for at least 14 days.
• A minimum of 4 HDD within the last 30 days before detoxification or cessation of alcohol use (a HDD is defined as 5 or more standard drinks per day for a man and 4 drinks for a woman; a standard drink is defined as 12 g of alcohol)

Exclusion criteria

• Significant alcohol withdrawal symptoms at screening
• Participating or starting in any formal treatment for AUD from visit 1 until completion of the double-blind phase
• Treatment with disulfiram during the study
• Past or present diagnosis of a DSM-5 psychotic or bipolar disorder in subjects or first-degree relatives
• Current suicidality or history of a serious suicide attempt

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

Switzerland · 2 centers

• University Hospital of Psychiatry, University of Basel — Basel
• University Hospital of Psychiatry, University of Bern — Bern

Identifiers

NCT: NCT05474989 · 2024-02125

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗